Publication

N-Glucuronide Metabolite of Camonsertib

Biosynthesis and identification of an N-Glucuronide Metabolite of Camonsertib

This paper published jointly by scientists at Repare Therapeutics, BioAgilytix and Hypha Discovery describes the synthesis of a prominent human N-glucuronide metabolite of camonsertib by microbial biotransformation, and its subsequent identification by NMR spectroscopy.

Abstract

Camonsertib is a novel ATR kinase inhibitor in clinical development for advanced cancers targeting sensitizing mutations. This article describes the identification and biosynthesis of an N-glucuronide metabolite of camonsertib.

This metabolite was first observed in human hepatocyte incubations and was subsequently isolated to determine the structure, evaluate its stability as part of bioanalytical method development and for use as a standard for estimating its concentration in phase I samples.

The N-glucuronide was scaled-up using a purified bacterial culture preparation and was subsequently isolated using preparative chromatography. The bacterial culture generated sufficient material of the glucuronide to allow for one- and two-dimensional 1H and 13C NMR structural elucidation and further bioanalytical characterization. The nuclear Overhauser effect data combined with the gradient heteronuclear multiple bond correlation experiment and molecular modeling, strongly suggests that the point of attachment of the glucuronide results in the formation of (2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-(5-(4-((1R,3r,5S)-3-hydroxy-8-oxabicyclo[3.2.1]octan-3-yl)-6-((R)-3-methylmorpholino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-1H-pyrazol-1-yl)tetrahydro-2H-pyran-2-carboxylic acid.

Highlights
  • Camonsertib is metabolised by phase I mechanisms and mainly by UGT1A4 to a single glucuronide
  • Challenging to pinpoint attachment by LC-MS/MS
  • Microbial biotransformation generated the specific N-glucuronide matching to the human hepatocyte product
  • NMR confirmed metabolite structure
  • Pure material also used for stability studies in human whole blood and plasma
  • N-glucuronide shown to be stable under typical bioanalytical sample processing conditions for formal method validation and eventual clinical sample analysis of camonsertib.
Paper

N-Glucuronide Metabolite of Camonsertib. Robert PappLaird TrimbleAdrian J. FretlandRavi ManoharRichard PhippsLisbet KvaernoAlexander L. PerrymanGregory Reynolds and W. Cameron Black.

Ready to begin? Our scientists are available to talk through your requirements

Contact Us 2

Don't forget to subscribe to our newsletter and blog!

Newsletter Signup
Which do you wish to signup for?